ClinicalTrials.gg
CompletedNCT00743652Updated Mar 15, 2012Results posted

Study Evaluating the Impact of the 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Alaskan Native Children.

A Phase 3 interventional study of 13-valent Pneumococcal Conjugate Vaccine and 13-valent Pneumococcal Conjugate Vaccine in Pneumococcal Disease and 13-valent Pneumococcal Vaccine, sponsored by Pfizer. Completed at 21 sites in United States. Open to participants aged 42 Days to 5 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2012-03-15.

Sponsored by Pfizer · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
373
Allocation
Non-randomized
Ages
42 Days to 5 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 44 studies testing 13-valent pneumococcal vaccine in Pneumococcal Infections — none open to participants now, 1 under way, none of them phase 3. 13-valent pneumococcal vaccine · Pneumococcal Infections.

Enrollment
20th of 44
373 · median 328
Started
2009
with 1 other
Phase 3
19 of 44
none open now
Registered
9th of 44
by date
Lead sponsor
16 of 44
Pfizer

Among the 44 studies testing 13-valent pneumococcal vaccine in Pneumococcal Infections, this one is the 20th largest by enrollment, is one of 2 that started in 2009, is one of 19 in phase 3, and was the 9th registered.

Pneumococcal Infections

298 studies on the registry are indexed under Pneumococcal Infections; 25 are open to participants now.

Browse Pneumococcal Infections studies →

Open to participants now

None of the 44 studies testing 13-valent pneumococcal vaccine in Pneumococcal Infections is open now. The open studies under Pneumococcal Infections, anywhere →

About 13-valent pneumococcal vaccine

13-valent pneumococcal vaccine: first FDA approval 2010 (Prevnar 13). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 20 Pneumococcal Infections studies recruiting now, 4 (20%) set no upper age limit and 14 (70%) stop at 75 or younger; 14 take children under 18; 16 take healthy volunteers.

This study: 42 Days to 5 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 44 studies testing 13-valent pneumococcal vaccine in Pneumococcal Infections as a file.
02

Study summary

This study is to evaluate the safety, immunogenicity and impact of 13-valent Pneumococcal conjugate vaccine in Alaskan Native Children.

03

Conditions studied

  • Pneumococcal Disease
  • 13-valent Pneumococcal Vaccine

Keywords

  • 13 valent Pneumococcal Conjugate Vaccine
  • Antibody Response
  • safety
  • Alaskan Native Children
04

Who can participate

Ages eligible
42 Days to 5 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female infants 6 weeks to \< 5years of age in good health, available for the entire study period and reachable by phone, parents able to complete all relevant study procedures.
  • Infants who have received Prevnar are eligible to participate, but this is not required.
  • Infants participating in the blood draws must live in a specific identified area (Yukon Kuskokwim Delta region)

Exclusion criteria

Exclusion Criteria:

  • to vaccination with pneumococcal vaccine or allergic reaction to any vaccines or vaccine related components, immune deficiency, bleeding disorder or major known congenital malformation.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
373 participants (actual)

Study arms

  • Experimental
    Group1

    Subjects 6 weeks to \<10 months of age with 0 prior dose of Prevnar.

    Biological: 13-valent Pneumococcal Conjugate Vaccine

  • Experimental
    Group 2

    Subjects \<12 months of age with 1 prior dose of Prevnar.

    Biological: 13-valent Pneumococcal Conjugate Vaccine

  • Experimental
    Group 3

    Subjects \<12 months of age with 2 prior doses of Prevnar.

    Biological: 13-valent Pneumococcal Conjugate Vaccine

  • Experimental
    Group 4

    Subjects ≥12 months to \<2 years of age.

    Biological: 13-valent Pneumococcal Conjugate Vaccine

  • Experimental
    Group 5

    Subjects ≥2 years to \<5 years of age

    Biological: 13-valent Pneumococcal Conjugate Vaccine

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving Serotype-Specific Pneumococcal Immunoglobulin G (IgG) Antibody Level ≥0.35 Micrograms Per Milliliter (Mcg/mL) 1 Month After the Infant Series

    Percentage of participants in 13vPnC Groups 1, 2 and 3 achieving predefined antibody threshold ≥0.35 mcg/mL along with the corresponding 95% confidence interval (CI) for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Exact 2-sided CI based upon the observed proportion of participants.

    Time frame: 28 to 56 days after vaccination 3 for Group 1, after vaccination 2 for Group 2, and after vaccination 1 for Group 3.

  2. Percentage of Participants Achieving Serotype-Specific Pneumococcal IgG Antibody Level ≥0.35 Mcg/mL 1 Month After the Toddler Dose

    Percentage of participants in 13vPnC Groups 1, 2, and 3 achieving predefined antibody threshold ≥0.35 mcg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Exact 2-sided CI based upon the observed proportion of participants.

    Time frame: 28 to 56 days after vaccination 4 for Group 1, after vaccination 3 for Group 2, and after vaccination 2 for Group 3.

  3. Percentage of Participants Achieving Serotype-specific Pneumococcal IgG Antibody Level ≥0.35 Mcg/mL 1 Month After the Relevant Catch-Up Dose

    Percentage of participants in 13vPnC Groups 4 and 5 achieving predefined antibody threshold ≥0.35 mcg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Exact 2-sided CI based upon the observed proportion of participants.

    Time frame: 28 to 56 days after vaccination 2 for Group 4, and after the single vaccination in Group 5.

Secondary outcomes

  1. Percentage of Participants Achieving Serum IgG Antibody Level ≥0.35 Mcg/mL Prior to Vaccination With 13vPnC (Groups 4 and 5 Only)

    Percentage of participants in 13vPnC Groups 4 and 5 achieving predefined antibody threshold ≥0.35 mcg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Exact 2-sided CI based upon the observed proportion of participants.

    Time frame: 28 to 56 days before vaccination 2 for Group 4, and before the single vaccination in Group 5.

  2. Percentage of Participants Achieving Serotype-specific Pneumococcal IgG Antibody Level ≥1.0 Mcg/mL 1 Month After the Infant Series

    Percentage of participants in 13vPnC Groups 1, 2, and 3 achieving predefined antibody threshold ≥1.0 mcg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Exact 2-sided CI based upon the observed proportion of participants.

    Time frame: 28 to 56 days after vaccination 3 for Group 1, after vaccination 2 for Group 2, and after vaccination 1 for Group 3.

  3. Percentage of Participants Achieving Serotype-specific Pneumococcal IgG Antibody Level ≥1.0 Mcg/mL 1 Month After the Toddler Dose

    Percentage of participants in 13vPnC Groups 1, 2, and 3 achieving predefined antibody threshold ≥1.0 mcg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Exact 2-sided CI based upon the observed proportion of participants.

    Time frame: 28 to 56 days after vaccination 4 for Group 1, after vaccination 3 for Group 2, and after vaccination 2 for Group 3.

  4. Percentage of Participants Achieving Serotype-specific Pneumococcal IgG Antibody Level ≥1.0 Mcg/mL 1 Month After the Relevant Catch-up Dose

    Percentage of participants in 13vPnC Groups 4 and 5 achieving predefined antibody threshold ≥1.0 mcg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Exact 2-sided CI based upon the observed proportion of participants.

    Time frame: 28 to 56 days after vaccination 2 for Group 4, and after the single vaccination in Group 5.

  5. Percentage of Participants Reporting Pre-Specified Local Reactions: Catch-up Dose 1

    Local reactions were reported by the parent/legal guardian using a diary card. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Redness and swelling were scaled as Any (redness or swelling present); Mild (0.5 centimeters \[cm\] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (\> 7.0 cm). Participants may have been represented in more than 1 category.

    Time frame: Day 1 through Day 7 after vaccination 1 for Group 4 and after the single vaccination in Group 5.

  6. Percentage of Participants Reporting Pre-Specified Local Reactions: Catch-up Dose 2

    Local reactions were reported by the parent/legal guardian using a diary card. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Redness and swelling were scaled as Any (redness or swelling present); Mild (0.5 centimeters \[cm\] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (\> 7.0 cm). Participants may have been represented in more than 1 category.

    Time frame: Day 1 through Day 7 after vaccination 2 for Group 4

  7. Percentage of Participants Reporting Pre-Specified Systemic Events: Catch-up Dose 1

    Systemic events (any fever 38 degrees Celsius \[C\] or higher, decreased appetite, irritability, increased sleep, decreased sleep, hives \[urticaria\], and use of antipyretic medication) were reported using a diary card. Participants may have been represented in more than 1 category.

    Time frame: Day 1 through Day 7 after vaccination 1 for Group 4 and after the single vaccination in Group 5.

  8. Percentage of Participants Reporting Pre-Specified Systemic Events: Catch-up Dose 2

    Systemic events (any fever 38 degrees C or higher, decreased appetite, irritability, increased sleep, decreased sleep, hives \[urticaria\], and use of antipyretic medication) were reported using a diary card. Participants may have been represented in more than 1 category.

    Time frame: Day 1 through Day 7 after vaccination 2 for Group 4

Other outcomes

  1. Number of Cases of Invasive Pneumococcal Disease (IPD) in Participants Less Than 5 Years of Age Due to Any Serotype Contained in 13vPnC

    In order to assess the impact of 13vPnC on the incidence of IPD in the Yukon Kuskokwim (YK) Delta region, the Centers for Disease Control and Prevention (CDC) Arctic Investigation Program (AIP) accessed IPD data through evaluation of ongoing statewide IPD surveillance in Alaska. The CDC's AIP followed IPD (including serotype and vaccination history) to show whether identified cases of IPD received Prevnar, 13vPnC, or both. These data were combined with statewide data and used to identify the overall trend in IPD in the YK Delta region after introduction of 13vPnC.

    Time frame: Baseline to 6 months after last vaccination

  2. Percentage of Participants Achieving Serotype-Specific Pneumococcal IgG Antibody Level ≥0.15 Mcg/mL 1 Month After the Infant Series

    Percentage of participants in 13vPnC Groups 1, 2, and 3 achieving predefined antibody threshold ≥0.15 mcg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Exact 2-sided CI based upon the observed proportion of participants.

    Time frame: 28 to 56 days after vaccination 3 for Group 1, after vaccination 2 for Group 2, and after vaccination 1 for Group 3.

  3. Percentage of Participants Achieving Serotype-specific Pneumococcal IgG Antibody Level ≥0.15 Mcg/mL 1 Month After the Toddler Dose

    Percentage of participants in 13vPnC Groups 1, 2, and 3 achieving predefined antibody threshold ≥0.15 mcg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Exact 2-sided CI based upon the observed proportion of participants.

    Time frame: 28 to 56 days after vaccination 4 for Group 1, after vaccination 3 for Group 2, and after vaccination 2 for Group 3.

  4. Percentage of Participants Achieving Serotype-specific Pneumococcal IgG Antibody Level ≥0.15 Mcg/mL 1 Month After the Relevant Catch-up Dose

    Percentage of participants in 13vPnC Groups 4 and 5 achieving predefined antibody threshold ≥0.15 mcg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Exact 2-sided CI based upon the observed proportion of participants.

    Time frame: 28 to 56 days after vaccination 2 for Group 4, and after the single vaccination in Group 5.

  5. Geometric Mean Concentration (GMC) for Serotype-Specific Pneumococcal IgG Antibodies 1 Month After the Infant Series

    Antibody GMCs (mcg/mL) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. GMC (13vPnC) with 2-sided 95% CIs were evaluated. CIs are back transformations of confidence levels based on Student t distribution for mean logarithm of concentrations. GMCs were calculated using all participants with available data for specified blood draw.

    Time frame: 28 to 56 days after vaccination 3 for Group 1, after vaccination 2 for Group 2, and after vaccination 1 for Group 3.

  6. GMC for Serotype-Specific Pneumococcal IgG Antibodies 1 Month After the Toddler Dose

    Antibody GMCs (mcg/mL) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A). GMC (13vPnC) with 2-sided 95% CIs were evaluated. CIs are back transformations of confidence levels based on Student t distribution for mean logarithm of concentrations. GMCs were calculated using all participants with available data for specified blood draw.

    Time frame: 28 to 56 days after vaccination 4 for Group 1, after vaccination 3 for Group 2, after vaccination 2 for Group 3.

  7. GMC for Serotype-specific Pneumococcal IgG Antibodies 1 Month After the Relevant Catch-up Dose

    Antibody GMCs (mcg/mL) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. GMC (13vPnC) with 2-sided 95% CIs were evaluated. CIs are back transformations of confidence levels based on Student t distribution for mean logarithm of concentrations. GMCs were calculated using all participants with available data for specified blood draw.

    Time frame: 28 to 56 days after vaccination 2 for Group 4, and after the single vaccination in Group 5.

  8. Percentage of Participants Achieving Opsonophagocytic Assay (OPA) Titers ≥Lower Limit of Quantitation (LLOQ) Measured 1 Month After the Infant Series

    Percentage of participants in 13vPnC Groups 1, 2, and 3 achieving OPA with 95% CI for serotypes 4, 6B, 9V, 14, 18C, 19F, 23F, 1, 3, 5, 6A, 7F, and 19A. Exact 2-sided CI based upon the observed proportion of participants. The LLOQ in titers for each serotype was: Pn001, 18; Pn003, 12; Pn004, 21; Pn005, 29; Pn06A, 37; Pn06B, 43, Pn7F, 210; Pn09V, 345; Pn014, 35; Pn18C, 31; Pn19A, 18; Pn19F, 48; and Pn23F, 13. Limit of detection (LOD) established as lowest titer possible in assay, which was 8. OPA titers below LLOQ set to 0.5\*LOD for analysis.

    Time frame: 28 to 56 days after vaccination 3 for Group 1, after vaccination 2 for Group 2, and after vaccination 1 for Group 3.

  9. Percentage of Participants Achieving OPA Titers ≥LLOQ Measured 1 Month After the Toddler Dose

    Percentage of participants in 13vPnC Groups 1, 2 and 3 achieving OPA with 95% CI for serotypes 4, 6B, 9V, 14, 18C, 19F, 23F, 1, 3, 5, 6A, 7F, and 19A. Exact 2-sided CI based upon the observed proportion of participants. The LLOQ in titers for each serotype was: Pn001, 18; Pn003, 12; Pn004, 21; Pn005, 29; Pn06A, 37; Pn06B, 43, Pn7F, 210; Pn09V, 345; Pn014, 35; Pn18C, 31; Pn19A, 18; Pn19F, 48; and Pn23F, 13. Limit of detection (LOD) established as lowest titer possible in assay, which was 8. OPA titers below LLOQ set to 0.5\*LOD for analysis.

    Time frame: 28 to 56 days after vaccination 4 for Group 1, after vaccination 3 for Group 2, and after vaccination 2 for Group 3.

  10. Percentage of Participants Achieving OPA Titers ≥LLOQ Measured 1 Month After the Relevant Catch-up Dose

    Percentage of participants in 13vPnC Groups 4 and 5 achieving OPA with 95% CI for serotypes 4, 6B, 9V, 14, 18C, 19F, 23F, 1, 3, 5, 6A, 7F, and 19A. Exact 2-sided CI based upon the observed proportion of participants. The LLOQ in titers for each serotype was: Pn001, 18; Pn003, 12; Pn004, 21; Pn005, 29; Pn06A, 37; Pn06B, 43, Pn7F, 210; Pn09V, 345; Pn014, 35; Pn18C, 31; Pn19A, 18; Pn19F, 48; and Pn23F, 13. Limit of detection (LOD) established as lowest titer possible in assay, which was 8. OPA titers below LLOQ set to 0.5\*LOD for analysis.

    Time frame: 28 to 56 days after vaccination 2 for Group 4, and after the single vaccination in Group 5.

  11. Pneumococcal OPA Geometric Mean Titers (GMTs) 1 Month After the Infant Series

    Antibody geometric mean titers as measured by OPA assay for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A). GMTs were calculated using all participants with available data for the specified blood draw. CIs for the GMTs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the titers.

    Time frame: 28 to 56 days after vaccination 3 for Group 1, after vaccination 2 for Group 2, and after vaccination 1 for Group 3.

  12. Pneumococcal OPA GMTs 1 Month After the Toddler Dose

    Antibody geometric mean titers as measured by OPA assay for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A). GMTs were calculated using all subjects with available data for the specified blood draw. CIs for the GMTs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the titers.

    Time frame: 28 to 56 days after vaccination 4 for Group 1, after vaccination 3 for Group 2, after vaccination 2 for Group 3.

  13. Pneumococcal OPA GMTs 1 Month After the Relevant Catch-up Dose

    Antibody geometric mean titers as measured by OPA assay for 13 pneumococcal serotypes (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). GMTs were calculated using all participants with available data for the specified blood draw. CIs for the GMTs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the titers.

    Time frame: 28 to 56 days after vaccination 2 for Group 4, and after the single vaccination in Group 5.

  14. Correlation of OPA and IgG Values for Each 13vPnC Serotype 1 Month After the Infant Series

    Time frame: 28 to 56 days after vaccination 3 for Group 1, after vaccination 2 for Group 2, and after vaccination 1 for Group 3.

  15. Correlation of OPA and IgG Values for Each 13vPnC Serotype 1 Month After the Toddler Dose

    Time frame: 28 to 56 days after vaccination 4 for Group 1, after vaccination 3 for Group 2, and after vaccination 2 for Group 3.

  16. Correlation of OPA and IgG Values for Each 13vPnC Serotype 1 Month After the Relevant Catch-up Dose

    Time frame: 28 to 56 days after vaccination 2 for Group 4, and after the single vaccination in Group 5.

07

Results

Posted Feb 10, 2012

Participant flow

Blood sample was optional for subjects living in the Bethel area. Active vaccination stopped when 13-valent pneumococcal conjugate vaccine (13vPnC) was commercially available in Alaska. Study ended after a 6-month follow-up for safety following the last vaccination.

Participant flow — Overall Study
Milestone13vPnC Group 1 (3 Doses Infant Series and 1 Toddler Dose)13vPnC Group 2 (2 Doses Infant Series and 1 Toddler Dose)13vPnC Group 3 (1 Dose Infant Series and 1 Toddler Dose)13vPnC Group 4 (2 Catch-Up Doses)13vPnC Group 5 (1 Catch-Up Dose)
Started15151256779
Vaccinated dose 115151256679
Vaccinated dose 2112410490
Vaccinated dose 3740000
Toddler dose15231600
Completed14148236379
Not completed103240
Withdrew: Parent/legal guardian request32220
Withdrew: Adverse event30000
Withdrew: Death20000
Withdrew: Investigator request00020
Withdrew: Other11000
Withdrew: Lost to follow-up10000

Outcome measures

PrimaryPercentage of Participants Achieving Serotype-Specific Pneumococcal Immunoglobulin G (IgG) Antibody Level ≥0.35 Micrograms Per Milliliter (Mcg/mL) 1 Month After the Infant Series

Percentage of participants in 13vPnC Groups 1, 2 and 3 achieving predefined antibody threshold ≥0.35 mcg/mL along with the corresponding 95% confidence interval (CI) for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Exact 2-sided CI based upon the observed proportion of participants.

Time frame:
28 to 56 days after vaccination 3 for Group 1, after vaccination 2 for Group 2, and after vaccination 1 for Group 3.
Reported as:
Number · Percentage of Participants
Percentage of Participants Achieving Serotype-Specific Pneumococcal Immunoglobulin G (IgG) Antibody Level ≥0.35 Micrograms Per Milliliter (Mcg/mL) 1 Month After the Infant Series
Percentage of Participants13vPnC Group 1 (3 Doses Infant Series and 1 Toddler Dose)13vPnC Group 2 (2 Doses Infant Series and 1 Toddler Dose)13vPnC Group 3 (1 Dose Infant Series and 1 Toddler Dose)
Common serotypes - serotype 4100.0 (71.5 to 100.0)100.0 (54.1 to 100.0)100.0 (29.2 to 100.0)
Common serotypes - serotype 6B100.0 (71.5 to 100.0)83.3 (35.9 to 99.6)100.0 (15.8 to 100.0)
Common serotypes - serotype 9V100.0 (71.5 to 100.0)83.3 (35.9 to 99.6)100.0 (29.2 to 100.0)
Common serotypes - serotype 1490.9 (58.7 to 99.8)100.0 (54.1 to 100.0)100.0 (15.8 to 100.0)
Common serotype - serotype 18C100.0 (71.5 to 100.0)100.0 (54.1 to 100.0)100.0 (29.2 to 100.0)
Common serotype - serotype 19F100.0 (71.5 to 100.0)100.0 (54.1 to 100.0)100.0 (29.2 to 100.0)
Common serotype - serotype 23F90.9 (58.7 to 99.8)83.3 (35.9 to 99.6)100.0 (29.2 to 100.0)
Additional serotype - serotype 1100.0 (71.5 to 100.0)100.0 (54.1 to 100.0)100.0 (29.2 to 100.0)
Additional serotype - serotype 390.9 (58.7 to 99.8)100.0 (54.1 to 100.0)100.0 (29.2 to 100.0)
Additional serotype - serotype 5100.0 (71.5 to 100.0)100.0 (54.1 to 100.0)100.0 (29.2 to 100.0)
Additional serotype - serotype 6A90.9 (58.7 to 99.8)100.0 (54.1 to 100.0)100.0 (29.2 to 100.0)
Additional serotype - serotype 7F100.0 (71.5 to 100.0)100.0 (54.1 to 100.0)100.0 (29.2 to 100.0)
Additional serotype - serotype 19A100.0 (71.5 to 100.0)100.0 (54.1 to 100.0)100.0 (29.2 to 100.0)
PrimaryPercentage of Participants Achieving Serotype-Specific Pneumococcal IgG Antibody Level ≥0.35 Mcg/mL 1 Month After the Toddler Dose

Percentage of participants in 13vPnC Groups 1, 2, and 3 achieving predefined antibody threshold ≥0.35 mcg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Exact 2-sided CI based upon the observed proportion of participants.

Time frame:
28 to 56 days after vaccination 4 for Group 1, after vaccination 3 for Group 2, and after vaccination 2 for Group 3.
Reported as:
Number · Percentage of Participants
Percentage of Participants Achieving Serotype-Specific Pneumococcal IgG Antibody Level ≥0.35 Mcg/mL 1 Month After the Toddler Dose
Percentage of Participants13vPnC Group 1 (3 Doses Infant Series and 1 Toddler Dose)13vPnC Group 2 (2 Doses Infant Series and 1 Toddler Dose)13vPnC Group 3 (1 Dose Infant Series and 1 Toddler Dose)
Common serotypes - serotype 4100.0 (15.8 to 100.0)100.0 (54.1 to 100.0)100.0 (15.8 to 100.0)
Common serotypes - serotype 6B100.0 (15.8 to 100.0)100.0 (54.1 to 100.0)100.0 (15.8 to 100.0)
Common serotypes - serotype 9V100.0 (15.8 to 100.0)100.0 (54.1 to 100.0)100.0 (15.8 to 100.0)
Common serotypes - serotype 14100.0 (15.8 to 100.0)100.0 (54.1 to 100.0)100.0 (15.8 to 100.0)
Common serotype - serotype 18C100.0 (15.8 to 100.0)100.0 (54.1 to 100.0)100.0 (15.8 to 100.0)
Common serotype - serotype 19F100.0 (15.8 to 100.0)100.0 (54.1 to 100.0)100.0 (15.8 to 100.0)
Common serotype - serotype 23F100.0 (15.8 to 100.0)100.0 (54.1 to 100.0)100.0 (15.8 to 100.0)
Additional serotype - serotype 1100.0 (15.8 to 100.0)100.0 (54.1 to 100.0)100.0 (15.8 to 100.0)
Additional serotype - serotype 3100.0 (15.8 to 100.0)100.0 (54.1 to 100.0)100.0 (15.8 to 100.0)
Additional serotype - serotype 5100.0 (15.8 to 100.0)100.0 (54.1 to 100.0)100.0 (15.8 to 100.0)
Additional serotype - serotype 6A100.0 (15.8 to 100.0)100.0 (54.1 to 100.0)100.0 (15.8 to 100.0)
Additional serotype - serotype 7F100.0 (15.8 to 100.0)100.0 (54.1 to 100.0)100.0 (15.8 to 100.0)
Additional serotype - serotype 19A100.0 (15.8 to 100.0)100.0 (54.1 to 100.0)100.0 (15.8 to 100.0)
PrimaryPercentage of Participants Achieving Serotype-specific Pneumococcal IgG Antibody Level ≥0.35 Mcg/mL 1 Month After the Relevant Catch-Up Dose

Percentage of participants in 13vPnC Groups 4 and 5 achieving predefined antibody threshold ≥0.35 mcg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Exact 2-sided CI based upon the observed proportion of participants.

Time frame:
28 to 56 days after vaccination 2 for Group 4, and after the single vaccination in Group 5.
Reported as:
Number · Percentage of Participants
Percentage of Participants Achieving Serotype-specific Pneumococcal IgG Antibody Level ≥0.35 Mcg/mL 1 Month After the Relevant Catch-Up Dose
Percentage of Participants13vPnC Group 4 (2 Catch-Up Doses)13vPnC Group 5 (1 Catch-Up Dose)
Common serotypes - serotype 4100.0 (39.8 to 100.0)100.0 (66.4 to 100.0)
Common serotypes - serotype 6B100.0 (39.8 to 100.0)100.0 (66.4 to 100.0)
Common serotypes - serotype 9V100.0 (39.8 to 100.0)100.0 (66.4 to 100.0)
Common serotypes - serotype 14100.0 (39.8 to 100.0)100.0 (66.4 to 100.0)
Common serotype - serotype 18C100.0 (39.8 to 100.0)100.0 (66.4 to 100.0)
Common serotype - serotype 19F100.0 (39.8 to 100.0)100.0 (66.4 to 100.0)
Common serotype - serotype 23F100.0 (39.8 to 100.0)100.0 (66.4 to 100.0)
Additional serotype - serotype 1100.0 (39.8 to 100.0)100.0 (66.4 to 100.0)
Additional serotype - serotype 3100.0 (39.8 to 100.0)100.0 (66.4 to 100.0)
Additional serotype - serotype 5100.0 (39.8 to 100.0)100.0 (66.4 to 100.0)
Additional serotype - serotype 6A100.0 (39.8 to 100.0)100.0 (66.4 to 100.0)
Additional serotype - serotype 7F100.0 (39.8 to 100.0)100.0 (66.4 to 100.0)
Additional serotype - serotype 19A100.0 (39.8 to 100.0)100.0 (66.4 to 100.0)
SecondaryPercentage of Participants Achieving Serum IgG Antibody Level ≥0.35 Mcg/mL Prior to Vaccination With 13vPnC (Groups 4 and 5 Only)

Percentage of participants in 13vPnC Groups 4 and 5 achieving predefined antibody threshold ≥0.35 mcg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Exact 2-sided CI based upon the observed proportion of participants.

Time frame:
28 to 56 days before vaccination 2 for Group 4, and before the single vaccination in Group 5.
Reported as:
Number · Percentage of Participants
Percentage of Participants Achieving Serum IgG Antibody Level ≥0.35 Mcg/mL Prior to Vaccination With 13vPnC (Groups 4 and 5 Only)
Percentage of Participants13vPnC Group 4 (2 Catch-Up Doses)13vPnC Group 5 (1 Catch-Up Dose)
Common serotypes - serotype 450.0 (6.8 to 93.2)50.0 (15.7 to 84.3)
Common serotypes - serotype 6B100.0 (39.8 to 100.0)88.9 (51.8 to 99.7)
Common serotypes - serotype 9V100.0 (39.8 to 100.0)66.7 (29.9 to 92.5)
Common serotypes - serotype 14100.0 (29.2 to 100.0)88.9 (51.8 to 99.7)
Common serotype - serotype 18C75.0 (19.4 to 99.4)33.3 (7.5 to 70.1)
Common serotype - serotype 19F100.0 (39.8 to 100.0)88.9 (51.8 to 99.7)
Common serotype - serotype 23F100.0 (39.8 to 100.0)88.9 (51.8 to 99.7)
Additional serotype - serotype 10.0 (0.0 to 60.2)12.5 (0.3 to 52.7)
Additional serotype - serotype 30.0 (0.0 to 60.2)37.5 (8.5 to 75.5)
Additional serotype - serotype 550.0 (6.8 to 93.2)100.0 (66.4 to 100.0)
Additional serotype - serotype 6A100.0 (39.8 to 100.0)88.9 (51.8 to 99.7)
Additional serotype - serotype 7F0.0 (0.0 to 60.2)33.3 (7.5 to 70.1)
Additional serotype - serotype 19A100.0 (39.8 to 100.0)88.9 (51.8 to 99.7)
SecondaryPercentage of Participants Achieving Serotype-specific Pneumococcal IgG Antibody Level ≥1.0 Mcg/mL 1 Month After the Infant Series

Percentage of participants in 13vPnC Groups 1, 2, and 3 achieving predefined antibody threshold ≥1.0 mcg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Exact 2-sided CI based upon the observed proportion of participants.

Time frame:
28 to 56 days after vaccination 3 for Group 1, after vaccination 2 for Group 2, and after vaccination 1 for Group 3.
Reported as:
Number · Percentage of Participants
Percentage of Participants Achieving Serotype-specific Pneumococcal IgG Antibody Level ≥1.0 Mcg/mL 1 Month After the Infant Series
Percentage of Participants13vPnC Group 1 (3 Doses Infant Series and 1 Toddler Dose)13vPnC Group 2 (2 Doses Infant Series and 1 Toddler Dose)13vPnC Group 3 (1 Dose Infant Series and 1 Toddler Dose)
Common serotypes - serotype 490.9 (58.7 to 99.8)100.0 (54.1 to 100.0)100.0 (29.2 to 100.0)
Common serotypes - serotype 6B72.7 (39.0 to 94.0)83.3 (35.9 to 99.6)100.0 (15.8 to 100.0)
Common serotypes - serotype 9V81.8 (48.2 to 97.7)66.7 (22.3 to 95.7)66.7 (9.4 to 99.2)
Common serotypes - serotype 1490.9 (58.7 to 99.8)83.3 (35.9 to 99.6)100.0 (15.8 to 100.0)
Common serotype - serotype 18C63.6 (30.8 to 89.1)83.3 (35.9 to 99.6)100.0 (29.2 to 100.0)
Common serotype - serotype 19F100.0 (71.5 to 100.0)66.7 (22.3 to 95.7)100.0 (29.2 to 100.0)
Common serotype - serotype 23F63.6 (30.8 to 89.1)50.0 (11.8 to 88.2)100.0 (29.2 to 100.0)
Additional serotype - serotype 181.8 (48.2 to 97.7)83.3 (35.9 to 99.6)100.0 (29.2 to 100.0)
Additional serotype - serotype 354.5 (23.4 to 83.3)66.7 (22.3 to 95.7)100.0 (29.2 to 100.0)
Additional serotype - serotype 581.8 (48.2 to 97.7)83.3 (35.9 to 99.6)66.7 (9.4 to 99.2)
Additional serotype - serotype 6A72.7 (39.0 to 94.0)83.3 (35.9 to 99.6)66.7 (9.4 to 99.2)
Additional serotype - serotype 7F100.0 (71.5 to 100.0)83.3 (35.9 to 99.6)100.0 (29.2 to 100.0)
Additional serotype - serotype 19A72.7 (39.0 to 94.0)50.0 (11.8 to 88.2)33.3 (0.8 to 90.6)
SecondaryPercentage of Participants Achieving Serotype-specific Pneumococcal IgG Antibody Level ≥1.0 Mcg/mL 1 Month After the Toddler Dose

Percentage of participants in 13vPnC Groups 1, 2, and 3 achieving predefined antibody threshold ≥1.0 mcg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Exact 2-sided CI based upon the observed proportion of participants.

Time frame:
28 to 56 days after vaccination 4 for Group 1, after vaccination 3 for Group 2, and after vaccination 2 for Group 3.
Reported as:
Number · Percentage of Participants
Percentage of Participants Achieving Serotype-specific Pneumococcal IgG Antibody Level ≥1.0 Mcg/mL 1 Month After the Toddler Dose
Percentage of Participants13vPnC Group 1 (3 Doses Infant Series and 1 Toddler Dose)13vPnC Group 2 (2 Doses Infant Series and 1 Toddler Dose)13vPnC Group 3 (1 Dose Infant Series and 1 Toddler Dose)
Common serotypes - serotype 4100.0 (15.8 to 100.0)100.0 (54.1 to 100.0)50.0 (1.3 to 98.7)
Common serotypes - serotype 6B100.0 (15.8 to 100.0)100.0 (54.1 to 100.0)100.0 (15.8 to 100.0)
Common serotypes - serotype 9V100.0 (15.8 to 100.0)100.0 (54.1 to 100.0)50.0 (1.3 to 98.7)
Common serotypes - serotype 14100.0 (15.8 to 100.0)100.0 (54.1 to 100.0)100.0 (15.8 to 100.0)
Common serotype - serotype 18C100.0 (15.8 to 100.0)83.3 (35.9 to 99.6)100.0 (15.8 to 100.0)
Common serotype - serotype 19F100.0 (15.8 to 100.0)83.3 (35.9 to 99.6)100.0 (15.8 to 100.0)
Common serotype - serotype 23F100.0 (15.8 to 100.0)83.3 (35.9 to 99.6)100.0 (15.8 to 100.0)
Additional serotype - serotype 1100.0 (15.8 to 100.0)83.3 (35.9 to 99.6)100.0 (15.8 to 100.0)
Additional serotype - serotype 350.0 (1.3 to 98.7)66.7 (22.3 to 95.7)100.0 (15.8 to 100.0)
Additional serotype - serotype 5100.0 (15.8 to 100.0)100.0 (54.1 to 100.0)100.0 (15.8 to 100.0)
Additional serotype - serotype 6A100.0 (15.8 to 100.0)100.0 (54.1 to 100.0)100.0 (15.8 to 100.0)
Additional serotype - serotype 7F100.0 (15.8 to 100.0)100.0 (54.1 to 100.0)100.0 (15.8 to 100.0)
Additional serotype - serotype 19A100.0 (15.8 to 100.0)100.0 (54.1 to 100.0)100.0 (15.8 to 100.0)
SecondaryPercentage of Participants Achieving Serotype-specific Pneumococcal IgG Antibody Level ≥1.0 Mcg/mL 1 Month After the Relevant Catch-up Dose

Percentage of participants in 13vPnC Groups 4 and 5 achieving predefined antibody threshold ≥1.0 mcg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Exact 2-sided CI based upon the observed proportion of participants.

Time frame:
28 to 56 days after vaccination 2 for Group 4, and after the single vaccination in Group 5.
Reported as:
Number · Percentage of Participants
Percentage of Participants Achieving Serotype-specific Pneumococcal IgG Antibody Level ≥1.0 Mcg/mL 1 Month After the Relevant Catch-up Dose
Percentage of Participants13vPnC Group 4 (2 Catch-Up Doses)13vPnC Group 5 (1 Catch-Up Dose)
Common serotypes - serotype 4100.0 (39.8 to 100.0)100.0 (66.4 to 100.0)
Common serotypes - serotype 6B100.0 (39.8 to 100.0)100.0 (66.4 to 100.0)
Common serotypes - serotype 9V100.0 (39.8 to 100.0)100.0 (66.4 to 100.0)
Common serotypes - serotype 14100.0 (39.8 to 100.0)100.0 (66.4 to 100.0)
Common serotype - serotype 18C100.0 (39.8 to 100.0)100.0 (66.4 to 100.0)
Common serotype - serotype 19F100.0 (39.8 to 100.0)100.0 (66.4 to 100.0)
Common serotype - serotype 23F100.0 (39.8 to 100.0)100.0 (66.4 to 100.0)
Additional serotype - serotype 1100.0 (39.8 to 100.0)66.7 (29.9 to 92.5)
Additional serotype - serotype 3100.0 (39.8 to 100.0)77.8 (40.0 to 97.2)
Additional serotype - serotype 5100.0 (39.8 to 100.0)88.9 (51.8 to 99.7)
Additional serotype - serotype 6A100.0 (39.8 to 100.0)88.9 (51.8 to 99.7)
Additional serotype - serotype 7F100.0 (39.8 to 100.0)100.0 (66.4 to 100.0)
Additional serotype - serotype 19A100.0 (39.8 to 100.0)100.0 (66.4 to 100.0)
SecondaryPercentage of Participants Reporting Pre-Specified Local Reactions: Catch-up Dose 1

Local reactions were reported by the parent/legal guardian using a diary card. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Redness and swelling were scaled as Any (redness or swelling present); Mild (0.5 centimeters \[cm\] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (\> 7.0 cm). Participants may have been represented in more than 1 category.

Time frame:
Day 1 through Day 7 after vaccination 1 for Group 4 and after the single vaccination in Group 5.
Reported as:
Number · Percentage of Participants
Percentage of Participants Reporting Pre-Specified Local Reactions: Catch-up Dose 1
Percentage of Participants13vPnC Group 4 (2 Catch-Up Doses)13vPnC Group 5 (1 Catch-Up Dose)
Tenderness: Any (n=65,77)32.348.1
Tenderness: Significant (n=63,77)3.29.1
Swelling: Any (n=64,77)7.87.8
Swelling: Mild (n=62,76)3.22.6
Swelling: Moderate (n=63,77)3.26.5
Swelling: Severe (n=63,77)1.62.6
Redness: Any (n=65,77)15.413.0
Redness: Mild (n=63,77)11.111.7
Redness: Moderate (n=64,77)4.75.2
Redness: Severe (n=63,77)1.62.6
SecondaryPercentage of Participants Reporting Pre-Specified Local Reactions: Catch-up Dose 2

Local reactions were reported by the parent/legal guardian using a diary card. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Redness and swelling were scaled as Any (redness or swelling present); Mild (0.5 centimeters \[cm\] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (\> 7.0 cm). Participants may have been represented in more than 1 category.

Time frame:
Day 1 through Day 7 after vaccination 2 for Group 4
Reported as:
Number · Percentage of Participants
Percentage of Participants Reporting Pre-Specified Local Reactions: Catch-up Dose 2
Percentage of Participants13vPnC Group 4 (2 Catch-Up Doses)
Tenderness: Any (n=49)36.7
Tenderness: Significant (n=49)10.2
Swelling: Any (n=48)10.4
Swelling: Mild (n=47)8.5
Swelling: Moderate (n=47)0.0
Swelling: Severe (n=47)0.0
Redness: Any (n=49)6.1
Redness: Mild (n=48)4.2
Redness: Moderate (n=48)0.0
Redness: Severe (n=48)0.0
SecondaryPercentage of Participants Reporting Pre-Specified Systemic Events: Catch-up Dose 1

Systemic events (any fever 38 degrees Celsius \[C\] or higher, decreased appetite, irritability, increased sleep, decreased sleep, hives \[urticaria\], and use of antipyretic medication) were reported using a diary card. Participants may have been represented in more than 1 category.

Time frame:
Day 1 through Day 7 after vaccination 1 for Group 4 and after the single vaccination in Group 5.
Reported as:
Number · Percentage of Participants
Percentage of Participants Reporting Pre-Specified Systemic Events: Catch-up Dose 1
Percentage of Participants13vPnC Group 4 (2 Catch-Up Doses)13vPnC Group 5 (1 Catch-Up Dose)
Fever ≥38 degrees C but ≤39 degrees C (n=35,47)42.927.7
Fever >39 degrees C but ≤40 degrees C (n=29,43)20.711.6
Fever >40 degrees C (n=28,40)7.10
Decreased appetite (n=66,77)31.824.7
Irritability (n=66,77)53.041.6
Increased sleep (n=66,77)33.322.1
Decreased sleep (n=66,77)24.211.7
Hives (urticaria) (n=66,77)3.02.6
Use of medication to treat symptoms (n=65,77)50.833.8
SecondaryPercentage of Participants Reporting Pre-Specified Systemic Events: Catch-up Dose 2

Systemic events (any fever 38 degrees C or higher, decreased appetite, irritability, increased sleep, decreased sleep, hives \[urticaria\], and use of antipyretic medication) were reported using a diary card. Participants may have been represented in more than 1 category.

Time frame:
Day 1 through Day 7 after vaccination 2 for Group 4
Reported as:
Number · Percentage of Participants
Percentage of Participants Reporting Pre-Specified Systemic Events: Catch-up Dose 2
Percentage of Participants13vPnC Group 4 (2 Catch-Up Doses)
Fever ≥38 degrees C but ≤39 degrees C (n=26)23.1
Fever >39 degrees C but ≤40 degrees C (n=22)9.1
Fever >40 degrees C (n=21)0.0
Decreased appetite (n=49)22.4
Irritability (n=49)57.1
Increased sleep (n=49)26.5
Decreased sleep (n=49)4.1
Hives (urticaria) (n=49)2.0
Use of medication to treat symptoms (n=49)42.9
Other pre-specifiedNumber of Cases of Invasive Pneumococcal Disease (IPD) in Participants Less Than 5 Years of Age Due to Any Serotype Contained in 13vPnC

In order to assess the impact of 13vPnC on the incidence of IPD in the Yukon Kuskokwim (YK) Delta region, the Centers for Disease Control and Prevention (CDC) Arctic Investigation Program (AIP) accessed IPD data through evaluation of ongoing statewide IPD surveillance in Alaska. The CDC's AIP followed IPD (including serotype and vaccination history) to show whether identified cases of IPD received Prevnar, 13vPnC, or both. These data were combined with statewide data and used to identify the overall trend in IPD in the YK Delta region after introduction of 13vPnC.

Time frame:
Baseline to 6 months after last vaccination
Reported as:
Number · Participants
Number of Cases of Invasive Pneumococcal Disease (IPD) in Participants Less Than 5 Years of Age Due to Any Serotype Contained in 13vPnC
Participants13vPnC (All Participants)
Number of Cases of Invasive Pneumococcal Disease (IPD) in Participants Less Than 5 Years of Age Due to Any Serotype Contained in 13vPnC0
Other pre-specifiedPercentage of Participants Achieving Serotype-Specific Pneumococcal IgG Antibody Level ≥0.15 Mcg/mL 1 Month After the Infant Series

Percentage of participants in 13vPnC Groups 1, 2, and 3 achieving predefined antibody threshold ≥0.15 mcg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Exact 2-sided CI based upon the observed proportion of participants.

Time frame:
28 to 56 days after vaccination 3 for Group 1, after vaccination 2 for Group 2, and after vaccination 1 for Group 3.
Reported as:
Number · Percentage of Participants
Percentage of Participants Achieving Serotype-Specific Pneumococcal IgG Antibody Level ≥0.15 Mcg/mL 1 Month After the Infant Series
Percentage of Participants13vPnC Group 1 (3 Doses Infant Series and 1 Toddler Dose)13vPnC Group 2 (2 Doses Infant Series and 1 Toddler Dose)13vPnC Group 3 (1 Dose Infant Series and 1 Toddler Dose)
Common serotypes - serotype 4100.0 (71.5 to 100.0)100.0 (54.1 to 100.0)100.0 (29.2 to 100.0)
Common serotypes - serotype 6B100.0 (71.5 to 100.0)100.0 (54.1 to 100.0)100.0 (15.8 to 100.0)
Common serotypes - serotype 9V100.0 (71.5 to 100.0)100.0 (54.1 to 100.0)100.0 (29.2 to 100.0)
Common serotypes - serotype 1490.9 (58.7 to 99.8)100.0 (54.1 to 100.0)100.0 (15.8 to 100.0)
Common serotype - serotype 18C100.0 (71.5 to 100.0)100.0 (54.1 to 100.0)100.0 (29.2 to 100.0)
Common serotype - serotype 19F100.0 (71.5 to 100.0)100.0 (54.1 to 100.0)100.0 (29.2 to 100.0)
Common serotype - serotype 23F100.0 (71.5 to 100.0)100.0 (54.1 to 100.0)100.0 (29.2 to 100.0)
Additional serotype - serotype 1100.0 (71.5 to 100.0)100.0 (54.1 to 100.0)100.0 (29.2 to 100.0)
Additional serotype - serotype 3100.0 (71.5 to 100.0)100.0 (54.1 to 100.0)100.0 (29.2 to 100.0)
Additional serotype - serotype 5100.0 (71.5 to 100.0)100.0 (54.1 to 100.0)100.0 (29.2 to 100.0)
Additional serotype - serotype 6A100.0 (71.5 to 100.0)100.0 (54.1 to 100.0)100.0 (29.2 to 100.0)
Additional serotype - serotype 7F100.0 (71.5 to 100.0)100.0 (54.1 to 100.0)100.0 (29.2 to 100.0)
Additional serotype - serotype 19A100.0 (71.5 to 100.0)100.0 (54.1 to 100.0)100.0 (29.2 to 100.0)
Other pre-specifiedPercentage of Participants Achieving Serotype-specific Pneumococcal IgG Antibody Level ≥0.15 Mcg/mL 1 Month After the Toddler Dose

Percentage of participants in 13vPnC Groups 1, 2, and 3 achieving predefined antibody threshold ≥0.15 mcg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Exact 2-sided CI based upon the observed proportion of participants.

Time frame:
28 to 56 days after vaccination 4 for Group 1, after vaccination 3 for Group 2, and after vaccination 2 for Group 3.
Reported as:
Number · Percentage of Participants
Percentage of Participants Achieving Serotype-specific Pneumococcal IgG Antibody Level ≥0.15 Mcg/mL 1 Month After the Toddler Dose
Percentage of Participants13vPnC Group 1 (3 Doses Infant Series and 1 Toddler Dose)13vPnC Group 2 (2 Doses Infant Series and 1 Toddler Dose)13vPnC Group 3 (1 Dose Infant Series and 1 Toddler Dose)
Common serotypes - serotype 4100.0 (15.8 to 100.0)100.0 (54.1 to 100.0)100.0 (15.8 to 100.0)
Common serotypes - serotype 6B100.0 (15.8 to 100.0)100.0 (54.1 to 100.0)100.0 (15.8 to 100.0)
Common serotypes - serotype 9V100.0 (15.8 to 100.0)100.0 (54.1 to 100.0)100.0 (15.8 to 100.0)
Common serotypes - serotype 14100.0 (15.8 to 100.0)100.0 (54.1 to 100.0)100.0 (15.8 to 100.0)
Common serotype - serotype 18C100.0 (15.8 to 100.0)100.0 (54.1 to 100.0)100.0 (15.8 to 100.0)
Common serotype - serotype 19F100.0 (15.8 to 100.0)100.0 (54.1 to 100.0)100.0 (15.8 to 100.0)
Common serotype - serotype 23F100.0 (15.8 to 100.0)100.0 (54.1 to 100.0)100.0 (15.8 to 100.0)
Additional serotype - serotype 1100.0 (15.8 to 100.0)100.0 (54.1 to 100.0)100.0 (15.8 to 100.0)
Additional serotype - serotype 3100.0 (15.8 to 100.0)100.0 (54.1 to 100.0)100.0 (15.8 to 100.0)
Additional serotype - serotype 5100.0 (15.8 to 100.0)100.0 (54.1 to 100.0)100.0 (15.8 to 100.0)
Additional serotype - serotype 6A100.0 (15.8 to 100.0)100.0 (54.1 to 100.0)100.0 (15.8 to 100.0)
Additional serotype - serotype 7F100.0 (15.8 to 100.0)100.0 (54.1 to 100.0)100.0 (15.8 to 100.0)
Additional serotype - serotype 19A100.0 (15.8 to 100.0)100.0 (54.1 to 100.0)100.0 (15.8 to 100.0)
Other pre-specifiedPercentage of Participants Achieving Serotype-specific Pneumococcal IgG Antibody Level ≥0.15 Mcg/mL 1 Month After the Relevant Catch-up Dose

Percentage of participants in 13vPnC Groups 4 and 5 achieving predefined antibody threshold ≥0.15 mcg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Exact 2-sided CI based upon the observed proportion of participants.

Time frame:
28 to 56 days after vaccination 2 for Group 4, and after the single vaccination in Group 5.
Reported as:
Number · Percentage of Participants
Percentage of Participants Achieving Serotype-specific Pneumococcal IgG Antibody Level ≥0.15 Mcg/mL 1 Month After the Relevant Catch-up Dose
Percentage of Participants13vPnC Group 4 (2 Catch-Up Doses)13vPnC Group 5 (1 Catch-Up Dose)
Common serotypes - serotype 4100.0 (39.8 to 100.0)100.0 (66.4 to 100.0)
Common serotypes - serotype 6B100.0 (39.8 to 100.0)100.0 (66.4 to 100.0)
Common serotypes - serotype 9V100.0 (39.8 to 100.0)100.0 (66.4 to 100.0)
Common serotypes - serotype 14100.0 (39.8 to 100.0)100.0 (66.4 to 100.0)
Common serotype - serotype 18C100.0 (39.8 to 100.0)100.0 (66.4 to 100.0)
Common serotype - serotype 19F100.0 (39.8 to 100.0)100.0 (66.4 to 100.0)
Common serotype - serotype 23F100.0 (39.8 to 100.0)100.0 (66.4 to 100.0)
Additional serotype - serotype 1100.0 (39.8 to 100.0)100.0 (66.4 to 100.0)
Additional serotype - serotype 3100.0 (39.8 to 100.0)100.0 (66.4 to 100.0)
Additional serotype - serotype 5100.0 (39.8 to 100.0)100.0 (66.4 to 100.0)
Additional serotype - serotype 6A100.0 (39.8 to 100.0)100.0 (66.4 to 100.0)
Additional serotype - serotype 7F100.0 (39.8 to 100.0)100.0 (66.4 to 100.0)
Additional serotype - serotype 19A100.0 (39.8 to 100.0)100.0 (66.4 to 100.0)
Other pre-specifiedGeometric Mean Concentration (GMC) for Serotype-Specific Pneumococcal IgG Antibodies 1 Month After the Infant Series

Antibody GMCs (mcg/mL) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. GMC (13vPnC) with 2-sided 95% CIs were evaluated. CIs are back transformations of confidence levels based on Student t distribution for mean logarithm of concentrations. GMCs were calculated using all participants with available data for specified blood draw.

Time frame:
28 to 56 days after vaccination 3 for Group 1, after vaccination 2 for Group 2, and after vaccination 1 for Group 3.
Reported as:
Geometric mean · mcg/mL
Geometric Mean Concentration (GMC) for Serotype-Specific Pneumococcal IgG Antibodies 1 Month After the Infant Series
mcg/mL13vPnC Group 1 (3 Doses Infant Series and 1 Toddler Dose)13vPnC Group 2 (2 Doses Infant Series and 1 Toddler Dose)13vPnC Group 3 (1 Dose Infant Series and 1 Toddler Dose)
Common serotypes - serotype 42.64 (1.55 to 4.49)2.11 (0.93 to 4.80)4.27 (0.49 to 37.05)
Common serotypes - serotype 6B2.74 (1.23 to 6.12)2.59 (0.55 to 12.26)28.60 (0.12 to 7043.76)
Common serotypes - serotype 9V1.38 (0.97 to 1.98)1.04 (0.46 to 2.38)1.60 (0.31 to 8.37)
Common serotypes - serotype 144.78 (1.71 to 13.33)4.08 (1.68 to 9.88)10.73 (0.06 to 1894.14)
Common serotype - serotype 18C1.83 (1.04 to 3.21)1.66 (0.92 to 2.98)2.99 (0.40 to 22.62)
Common serotype - serotype 19F3.55 (2.10 to 6.01)1.61 (0.65 to 4.01)2.37 (1.43 to 3.93)
Common serotype - serotype 23F1.54 (0.79 to 3.01)1.03 (0.35 to 3.04)3.37 (1.18 to 9.66)
Additional serotype - serotype 13.33 (1.68 to 6.62)3.02 (1.06 to 8.60)2.87 (0.30 to 27.24)
Additional serotype - serotype 30.79 (0.51 to 1.22)1.61 (0.62 to 4.16)5.07 (1.53 to 16.79)
Additional serotype - serotype 52.89 (1.57 to 5.31)1.93 (1.14 to 3.26)1.75 (0.25 to 12.25)
Additional serotype - serotype 6A2.19 (0.93 to 5.16)2.48 (0.91 to 6.78)5.41 (0.01 to 2495.50)
Additional serotype - serotype 7F3.34 (1.99 to 5.61)3.18 (1.24 to 8.12)6.21 (1.84 to 20.92)
Additional serotype - serotype 19A1.87 (1.11 to 3.17)1.35 (0.56 to 3.25)0.97 (0.37 to 2.53)
Other pre-specifiedGMC for Serotype-Specific Pneumococcal IgG Antibodies 1 Month After the Toddler Dose

Antibody GMCs (mcg/mL) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A). GMC (13vPnC) with 2-sided 95% CIs were evaluated. CIs are back transformations of confidence levels based on Student t distribution for mean logarithm of concentrations. GMCs were calculated using all participants with available data for specified blood draw.

Time frame:
28 to 56 days after vaccination 4 for Group 1, after vaccination 3 for Group 2, after vaccination 2 for Group 3.
Reported as:
Geometric mean · mcg/mL
GMC for Serotype-Specific Pneumococcal IgG Antibodies 1 Month After the Toddler Dose
mcg/mL13vPnC Group 1 (3 Doses Infant Series and 1 Toddler Dose)13vPnC Group 2 (2 Doses Infant Series and 1 Toddler Dose)13vPnC Group 3 (1 Dose Infant Series and 1 Toddler Dose)
Common serotypes - serotype 47.16 (0.00 to 199911.7)2.55 (1.44 to 4.53)1.76 (0.00 to 4004.84)
Common serotypes - serotype 6B13.64 (0.00 to NA)12.01 (4.23 to 34.08)11.32 (0.01 to 11544.32)
Common serotypes - serotype 9V2.17 (0.01 to 373.79)2.20 (1.30 to 3.73)1.30 (0.00 to 2387.89)
Common serotypes - serotype 1412.18 (0.06 to 2411.14)11.42 (5.90 to 22.12)8.54 (0.19 to 377.53)
Common serotype - serotype 18C2.35 (0.00 to 1681.49)2.22 (1.22 to 4.03)2.42 (0.08 to 72.55)
Common serotype - serotype 19F11.00 (0.00 to 11762036)2.84 (1.03 to 7.79)3.65 (0.00 to 130178.5)
Common serotype - serotype 23F3.79 (0.00 to 66245120)2.35 (0.88 to 6.27)3.96 (NA to NA)
Additional serotype - serotype 12.15 (0.00 to 9338.28)4.19 (1.46 to 12.02)16.70 (0.00 to 5685164)
Additional serotype - serotype 30.73 (0.00 to 276.18)1.32 (0.63 to 2.78)1.63 (1.19 to 2.23)
Additional serotype - serotype 54.69 (0.00 to 36146.55)3.56 (1.96 to 6.46)5.85 (0.02 to 1606.11)
Additional serotype - serotype 6A17.14 (0.00 to NA)7.79 (3.00 to 20.21)3.24 (0.01 to 1555.15)
Additional serotype - serotype 7F7.45 (0.47 to 117.40)5.55 (2.59 to 11.87)4.50 (0.05 to 440.58)
Additional serotype - serotype 19A10.53 (2.63 to 42.07)3.21 (1.23 to 8.39)8.86 (0.00 to 8014211)
Other pre-specifiedGMC for Serotype-specific Pneumococcal IgG Antibodies 1 Month After the Relevant Catch-up Dose

Antibody GMCs (mcg/mL) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. GMC (13vPnC) with 2-sided 95% CIs were evaluated. CIs are back transformations of confidence levels based on Student t distribution for mean logarithm of concentrations. GMCs were calculated using all participants with available data for specified blood draw.

Time frame:
28 to 56 days after vaccination 2 for Group 4, and after the single vaccination in Group 5.
Reported as:
Geometric mean · mcg/mL
GMC for Serotype-specific Pneumococcal IgG Antibodies 1 Month After the Relevant Catch-up Dose
mcg/mL13vPnC Group 4 (2 Catch-Up Doses)13vPnC Group 5 (1 Catch-Up Dose)
Common serotypes - serotype 44.16 (1.16 to 14.91)4.92 (1.94 to 12.50)
Common serotypes - serotype 6B16.49 (4.31 to 63.06)22.94 (10.84 to 48.52)
Common serotypes - serotype 9V3.22 (1.20 to 8.64)5.16 (2.34 to 11.37)
Common serotypes - serotype 149.02 (2.18 to 37.29)16.99 (6.08 to 47.48)
Common serotype - serotype 18C4.22 (2.22 to 8.05)5.08 (2.43 to 10.63)
Common serotype - serotype 19F3.39 (0.78 to 14.78)6.45 (4.23 to 9.83)
Common serotype - serotype 23F4.94 (1.82 to 13.41)5.41 (2.30 to 12.74)
Additional serotype - serotype 19.37 (2.89 to 30.34)1.25 (0.64 to 2.46)
Additional serotype - serotype 31.65 (1.13 to 2.40)1.91 (1.06 to 3.46)
Additional serotype - serotype 54.51 (2.77 to 7.34)2.31 (1.41 to 3.78)
Additional serotype - serotype 6A7.42 (1.77 to 31.06)4.46 (2.09 to 9.48)
Additional serotype - serotype 7F8.81 (3.32 to 23.39)3.14 (1.93 to 5.08)
Additional serotype - serotype 19A4.40 (2.96 to 6.54)5.61 (2.69 to 11.70)
Other pre-specifiedPercentage of Participants Achieving Opsonophagocytic Assay (OPA) Titers ≥Lower Limit of Quantitation (LLOQ) Measured 1 Month After the Infant Series

Percentage of participants in 13vPnC Groups 1, 2, and 3 achieving OPA with 95% CI for serotypes 4, 6B, 9V, 14, 18C, 19F, 23F, 1, 3, 5, 6A, 7F, and 19A. Exact 2-sided CI based upon the observed proportion of participants. The LLOQ in titers for each serotype was: Pn001, 18; Pn003, 12; Pn004, 21; Pn005, 29; Pn06A, 37; Pn06B, 43, Pn7F, 210; Pn09V, 345; Pn014, 35; Pn18C, 31; Pn19A, 18; Pn19F, 48; and Pn23F, 13. Limit of detection (LOD) established as lowest titer possible in assay, which was 8. OPA titers below LLOQ set to 0.5\*LOD for analysis.

Time frame:
28 to 56 days after vaccination 3 for Group 1, after vaccination 2 for Group 2, and after vaccination 1 for Group 3.
Reported as:
Number · Percentage of Participants
Percentage of Participants Achieving Opsonophagocytic Assay (OPA) Titers ≥Lower Limit of Quantitation (LLOQ) Measured 1 Month After the Infant Series
Percentage of Participants13vPnC Group 1 (3 Doses Infant Series and 1 Toddler Dose)13vPnC Group 2 (2 Doses Infant Series and 1 Toddler Dose)13vPnC Group 3 (1 Dose Infant Series and 1 Toddler Dose)
Common serotypes - serotype 488.9 (51.8 to 99.7)75.0 (19.4 to 99.4)66.7 (9.4 to 99.2)
Common serotypes - serotype 6B100.0 (66.4 to 100.0)100.0 (39.8 to 100.0)100.0 (15.8 to 100.0)
Common serotypes - serotype 9V30.0 (6.7 to 65.2)0.0 (0.0 to 70.8)66.7 (9.4 to 99.2)
Common serotypes - serotype 14100.0 (54.1 to 100.0)75.0 (19.4 to 99.4)100.0 (15.8 to 100.0)
Common serotype - serotype 18C100.0 (59.0 to 100.0)100.0 (39.8 to 100.0)100.0 (15.8 to 100.0)
Common serotype - serotype 19F88.9 (51.8 to 99.7)50.0 (6.8 to 93.2)0.0 (0.0 to 97.5)
Common serotype - serotype 23F88.9 (51.8 to 99.7)66.7 (9.4 to 99.2)100.0 (15.8 to 100.0)
Additional serotype - serotype 160.0 (26.2 to 87.8)0.0 (0.0 to 60.2)33.3 (0.8 to 90.6)
Additional serotype - serotype 390.9 (58.7 to 99.8)100.0 (47.8 to 100.0)100.0 (29.2 to 100.0)
Additional serotype - serotype 570.0 (34.8 to 93.3)60.0 (14.7 to 94.7)33.3 (0.8 to 90.6)
Additional serotype - serotype 6A90.0 (55.5 to 99.7)100.0 (47.8 to 100.0)100.0 (29.2 to 100.0)
Additional serotype - serotype 7F100.0 (69.2 to 100.0)100.0 (47.8 to 100.0)100.0 (15.8 to 100.0)
Additional serotype - serotype 19A80.0 (44.4 to 97.5)75.0 (19.4 to 99.4)100.0 (15.8 to 100.0)
Other pre-specifiedPercentage of Participants Achieving OPA Titers ≥LLOQ Measured 1 Month After the Toddler Dose

Percentage of participants in 13vPnC Groups 1, 2 and 3 achieving OPA with 95% CI for serotypes 4, 6B, 9V, 14, 18C, 19F, 23F, 1, 3, 5, 6A, 7F, and 19A. Exact 2-sided CI based upon the observed proportion of participants. The LLOQ in titers for each serotype was: Pn001, 18; Pn003, 12; Pn004, 21; Pn005, 29; Pn06A, 37; Pn06B, 43, Pn7F, 210; Pn09V, 345; Pn014, 35; Pn18C, 31; Pn19A, 18; Pn19F, 48; and Pn23F, 13. Limit of detection (LOD) established as lowest titer possible in assay, which was 8. OPA titers below LLOQ set to 0.5\*LOD for analysis.

Time frame:
28 to 56 days after vaccination 4 for Group 1, after vaccination 3 for Group 2, and after vaccination 2 for Group 3.
Reported as:
Number · Percentage of Participants
Percentage of Participants Achieving OPA Titers ≥LLOQ Measured 1 Month After the Toddler Dose
Percentage of Participants13vPnC Group 1 (3 Doses Infant Series and 1 Toddler Dose)13vPnC Group 2 (2 Doses Infant Series and 1 Toddler Dose)13vPnC Group 3 (1 Dose Infant Series and 1 Toddler Dose)
Common serotypes - serotype 4100.0 (15.8 to 100.0)50.0 (11.8 to 88.2)100.0 (2.5 to 100.0)
Common serotypes - serotype 6B100.0 (15.8 to 100.0)80.0 (28.4 to 99.5)100.0 (2.5 to 100.0)
Common serotypes - serotype 9V100.0 (15.8 to 100.0)83.3 (35.9 to 99.6)100.0 (2.5 to 100.0)
Common serotypes - serotype 14100.0 (15.8 to 100.0)100.0 (29.2 to 100.0)100.0 (2.5 to 100.0)
Common serotype - serotype 18C100.0 (2.5 to 100.0)80.0 (28.4 to 99.5)100.0 (2.5 to 100.0)
Common serotype - serotype 19F100.0 (15.8 to 100.0)60.0 (14.7 to 94.7)100.0 (2.5 to 100.0)
Common serotype - serotype 23F100.0 (15.8 to 100.0)100.0 (47.8 to 100.0)100.0 (2.5 to 100.0)
Additional serotype - serotype 1100.0 (15.8 to 100.0)83.3 (35.9 to 99.6)100.0 (2.5 to 100.0)
Additional serotype - serotype 3100.0 (15.8 to 100.0)100.0 (54.1 to 100.0)100.0 (2.5 to 100.0)
Additional serotype - serotype 5100.0 (15.8 to 100.0)66.7 (22.3 to 95.7)100.0 (2.5 to 100.0)
Additional serotype - serotype 6A100.0 (15.8 to 100.0)100.0 (54.1 to 100.0)100.0 (2.5 to 100.0)
Additional serotype - serotype 7F100.0 (15.8 to 100.0)100.0 (54.1 to 100.0)100.0 (2.5 to 100.0)
Additional serotype - serotype 19A100.0 (15.8 to 100.0)100.0 (47.8 to 100.0)100.0 (2.5 to 100.0)
Other pre-specifiedPercentage of Participants Achieving OPA Titers ≥LLOQ Measured 1 Month After the Relevant Catch-up Dose

Percentage of participants in 13vPnC Groups 4 and 5 achieving OPA with 95% CI for serotypes 4, 6B, 9V, 14, 18C, 19F, 23F, 1, 3, 5, 6A, 7F, and 19A. Exact 2-sided CI based upon the observed proportion of participants. The LLOQ in titers for each serotype was: Pn001, 18; Pn003, 12; Pn004, 21; Pn005, 29; Pn06A, 37; Pn06B, 43, Pn7F, 210; Pn09V, 345; Pn014, 35; Pn18C, 31; Pn19A, 18; Pn19F, 48; and Pn23F, 13. Limit of detection (LOD) established as lowest titer possible in assay, which was 8. OPA titers below LLOQ set to 0.5\*LOD for analysis.

Time frame:
28 to 56 days after vaccination 2 for Group 4, and after the single vaccination in Group 5.
Reported as:
Number · Percentage of Participants
Percentage of Participants Achieving OPA Titers ≥LLOQ Measured 1 Month After the Relevant Catch-up Dose
Percentage of Participants13vPnC Group 4 (2 Catch-Up Doses)13vPnC Group 5 (1 Catch-Up Dose)
Common serotypes - serotype 4100.0 (29.2 to 100.0)100.0 (63.1 to 100.0)
Common serotypes - serotype 6B100.0 (29.2 to 100.0)100.0 (54.1 to 100.0)
Common serotypes - serotype 9V100.0 (39.8 to 100.0)100.0 (54.1 to 100.0)
Common serotypes - serotype 14100.0 (15.8 to 100.0)100.0 (54.1 to 100.0)
Common serotype - serotype 18C100.0 (29.2 to 100.0)100.0 (54.1 to 100.0)
Common serotype - serotype 19F100.0 (29.2 to 100.0)100.0 (54.1 to 100.0)
Common serotype - serotype 23F100.0 (29.2 to 100.0)100.0 (54.1 to 100.0)
Additional serotype - serotype 1100.0 (39.8 to 100.0)87.5 (47.3 to 99.7)
Additional serotype - serotype 3100.0 (39.8 to 100.0)100.0 (63.1 to 100.0)
Additional serotype - serotype 5100.0 (39.8 to 100.0)75.0 (34.9 to 96.8)
Additional serotype - serotype 6A100.0 (39.8 to 100.0)87.5 (47.3 to 99.7)
Additional serotype - serotype 7F100.0 (39.8 to 100.0)100.0 (63.1 to 100.0)
Additional serotype - serotype 19A100.0 (39.8 to 100.0)100.0 (47.8 to 100.0)
Other pre-specifiedPneumococcal OPA Geometric Mean Titers (GMTs) 1 Month After the Infant Series

Antibody geometric mean titers as measured by OPA assay for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A). GMTs were calculated using all participants with available data for the specified blood draw. CIs for the GMTs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the titers.

Time frame:
28 to 56 days after vaccination 3 for Group 1, after vaccination 2 for Group 2, and after vaccination 1 for Group 3.
Reported as:
Geometric mean · Titers
Pneumococcal OPA Geometric Mean Titers (GMTs) 1 Month After the Infant Series
Titers13vPnC Group 1 (3 Doses Infant Series and 1 Toddler Dose)13vPnC Group 2 (2 Doses Infant Series and 1 Toddler Dose)13vPnC Group 3 (1 Dose Infant Series and 1 Toddler Dose)
Common serotypes - serotype 4123 (38.4 to 390.6)116 (3.1 to 4294.7)36 (0.3 to 4185.7)
Common serotypes - serotype 9V20 (3.1 to 123.1)4 (NA to NA)120 (0.1 to 199619.2)
Common serotype - serotype 19F151 (49.6 to 457.7)31 (0.7 to 1348.9)4 (NA to NA)
Common serotype - serotype 23F299 (79.5 to 1124.8)81 (0.1 to 52488.1)566 (182.6 to 1755.9)
Additional serotype - serotype 141 (9.2 to 183.5)4 (NA to NA)7 (0.5 to 109.4)
Additional serotype - serotype 358 (28.9 to 117.7)82 (21.7 to 311.6)206 (66.1 to 639.0)
Additional serotype - serotype 526 (9.6 to 72.3)18 (2.9 to 110.8)9 (0.3 to 234.2)
Additional serotype - serotype 6A731 (182.2 to 2933.6)1069 (337.1 to 3390.4)984 (179.7 to 5383.5)
Additional serotype - serotype 7F1396 (790.5 to 2467.0)1177 (692.5 to 2001.6)3485 (2308.5 to 5261.5)
Common serotype - serotype 6B1280 (610.3 to 2683.5)1450 (370.4 to 5675.6)1790 (0.0 to 72147076)
Common serotype - serotype 14332 (98.0 to 1124.2)71 (3.3 to 1516.0)449 (0.1 to 2059598)
Common serotype - serotype 18C868 (304.4 to 2475.0)452 (67.7 to 3023.6)906 (0.6 to 1340206)
Additional serotype - serotype 19A58 (17.7 to 191.3)158 (2.5 to 9872.6)380 (0.0 to NA)
Other pre-specifiedPneumococcal OPA GMTs 1 Month After the Toddler Dose

Antibody geometric mean titers as measured by OPA assay for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A). GMTs were calculated using all subjects with available data for the specified blood draw. CIs for the GMTs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the titers.

Time frame:
28 to 56 days after vaccination 4 for Group 1, after vaccination 3 for Group 2, after vaccination 2 for Group 3.
Reported as:
Geometric mean · Titers
Pneumococcal OPA GMTs 1 Month After the Toddler Dose
Titers13vPnC Group 1 (3 Doses Infant Series and 1 Toddler Dose)13vPnC Group 2 (2 Doses Infant Series and 1 Toddler Dose)13vPnC Group 3 (1 Dose Infant Series and 1 Toddler Dose)
Common serotypes - serotype 4599 (422.4 to 850.2)58 (2.6 to 1317.2)220 (NA to NA)
Common serotypes - serotype 9V428 (68.2 to 2681.9)460 (35.0 to 6035.8)2765 (NA to NA)
Common serotypes - serotype 14775 (5.8 to 104290.7)551 (73.6 to 4120.2)779 (NA to NA)
Common serotype - serotype 18C3311 (NA to NA)387 (14.8 to 10145.6)4316 (NA to NA)
Additional serotype - serotype 146 (0.1 to 14754.5)66 (14.4 to 305.2)165 (NA to NA)
Additional serotype - serotype 3159 (0.2 to 141793.2)138 (60.9 to 313.7)402 (NA to NA)
Additional serotype - serotype 587 (0.8 to 9175.7)30 (5.4 to 164.2)88 (NA to NA)
Additional serotype - serotype 7F4590 (258.5 to 81484.1)1575 (810.3 to 3061.7)6105 (NA to NA)
Additional serotype - serotype 19A1259 (210.3 to 7542.2)140 (22.7 to 860.3)427 (NA to NA)
Common serotype - serotype 6B1565 (0.0 to NA)605 (17.1 to 21473.7)12470 (NA to NA)
Common serotype - serotype 19F397 (0.0 to NA)73 (2.5 to 2087.3)532 (NA to NA)
Common serotype - serotype 23F227 (0.0 to NA)313 (30.6 to 3195.2)1660 (NA to NA)
Additional serotype - serotype 6A3207 (0.0 to NA)1688 (480.3 to 5929.3)6954 (NA to NA)
Other pre-specifiedPneumococcal OPA GMTs 1 Month After the Relevant Catch-up Dose

Antibody geometric mean titers as measured by OPA assay for 13 pneumococcal serotypes (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). GMTs were calculated using all participants with available data for the specified blood draw. CIs for the GMTs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the titers.

Time frame:
28 to 56 days after vaccination 2 for Group 4, and after the single vaccination in Group 5.
Reported as:
Geometric mean · Titers
Pneumococcal OPA GMTs 1 Month After the Relevant Catch-up Dose
Titers13vPnC Group 4 (2 Catch-Up Doses)13vPnC Group 5 (1 Catch-Up Dose)
Common serotypes - serotype 4594 (107.1 to 3295.5)1165 (261.1 to 5197.9)
Common serotypes - serotype 6B7236 (3423.7 to 15294.0)6795 (795.9 to 58012.5)
Common serotypes - serotype 9V2748 (457.9 to 16485.4)2979 (883.6 to 10040.5)
Common serotypes - serotype 141159 (31.2 to 42979.5)1547 (347.4 to 6892.2)
Common serotype - serotype 18C5910 (1824.6 to 19141.1)1871 (915.7 to 3824.2)
Common serotype - serotype 19F1584 (463.4 to 5417.3)594 (84.8 to 4164.9)
Common serotype - serotype 23F2870 (2572.2 to 3203.4)1240 (423.0 to 3632.5)
Additional serotype - serotype 1402 (285.8 to 564.7)62 (18.0 to 211.6)
Additional serotype - serotype 3218 (102.0 to 466.8)202 (136.0 to 299.3)
Additional serotype - serotype 5128 (15.9 to 1032.0)63 (13.3 to 302.2)
Additional serotype - serotype 6A9067 (5187.0 to 15848.5)2292 (231.2 to 22724.0)
Additional serotype - serotype 7F7776 (3701.3 to 16335.8)6086 (2680.9 to 13818.2)
Additional serotype - serotype 19A815 (549.9 to 1206.8)400 (68.4 to 2344.7)
Other pre-specifiedCorrelation of OPA and IgG Values for Each 13vPnC Serotype 1 Month After the Infant Series
Time frame:
28 to 56 days after vaccination 3 for Group 1, after vaccination 2 for Group 2, and after vaccination 1 for Group 3.
Reported as:
Number · Participants
Correlation of OPA and IgG Values for Each 13vPnC Serotype 1 Month After the Infant Series
Participants13vPnC Group 1 (3 Doses Infant Series and 1 Toddler Dose)13vPnC Group 2 (2 Doses Infant Series and 1 Toddler Dose)13vPnC Group 3 (1 Dose Infant Series and 1 Toddler Dose)
Correlation of OPA and IgG Values for Each 13vPnC Serotype 1 Month After the Infant SeriesNANANA
Other pre-specifiedCorrelation of OPA and IgG Values for Each 13vPnC Serotype 1 Month After the Toddler Dose
Time frame:
28 to 56 days after vaccination 4 for Group 1, after vaccination 3 for Group 2, and after vaccination 2 for Group 3.
Reported as:
Number · Participants
Correlation of OPA and IgG Values for Each 13vPnC Serotype 1 Month After the Toddler Dose
Participants13vPnC Group 1 (3 Doses Infant Series and 1 Toddler Dose)13vPnC Group 2 (2 Doses Infant Series and 1 Toddler Dose)13vPnC Group 3 (1 Dose Infant Series and 1 Toddler Dose)
Correlation of OPA and IgG Values for Each 13vPnC Serotype 1 Month After the Toddler DoseNANANA
Other pre-specifiedCorrelation of OPA and IgG Values for Each 13vPnC Serotype 1 Month After the Relevant Catch-up Dose
Time frame:
28 to 56 days after vaccination 2 for Group 4, and after the single vaccination in Group 5.
Reported as:
Number · Participants
Correlation of OPA and IgG Values for Each 13vPnC Serotype 1 Month After the Relevant Catch-up Dose
Participants13vPnC Group 4 (2 Catch-Up Doses)13vPnC Group 5 (1 Catch-Up Dose)
Correlation of OPA and IgG Values for Each 13vPnC Serotype 1 Month After the Relevant Catch-up DoseNANA

Adverse events

Collected over Randomization to 6 months after last vaccination. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Group 1 (Infant Series)—21/151 (13.9%)11/151 (7.3%)
Group 2 (Infant Series)—2/51 (3.9%)4/51 (7.8%)
Group 3 (Infant Series)—1/25 (4%)1/25 (4%)
Group 1 (Toddler Dose)—0/15 (0%)0/15 (0%)
Group 2 (Toddler Dose)—0/23 (0%)0/23 (0%)
Group 3 (Toddler Dose)—2/16 (12.5%)0/16 (0%)
Group 4 (2 Catch-Up Doses)—3/66 (4.5%)1/66 (1.5%)
Group 5 (1 Catch-Up Dose)—0/79 (0%)0/79 (0%)
Most frequent serious events
Showing 10 of 28
Most frequent serious events
EventGroup 1 (Infant Series)Group 2 (Infant Series)Group 3 (Infant Series)Group 1 (Toddler Dose)Group 2 (Toddler Dose)Group 3 (Toddler Dose)Group 4 (2 Catch-Up Doses)Group 5 (1 Catch-Up Dose)
LaryngomalaciaCongenital, familial and genetic disorders0/1510/510/250/150/231/160/660/79
Respiratory distressRespiratory, thoracic and mediastinal disorders1/1510/510/250/150/231/160/660/79
Gastrooesophageal reflux diseaseGastrointestinal disorders0/1510/510/250/150/231/160/660/79
HerpanginaInfections and infestations0/1510/510/250/150/231/160/660/79
DehydrationMetabolism and nutrition disorders0/1510/510/250/150/231/160/660/79
Breath holdingPsychiatric disorders0/1510/510/250/150/231/160/660/79
PneumoniaInfections and infestations4/1510/511/250/150/230/161/660/79
InfluenzaInfections and infestations3/1511/511/250/150/230/161/660/79
Meningitis viralInfections and infestations0/1510/511/250/150/230/160/660/79
ApnoeaRespiratory, thoracic and mediastinal disorders0/1510/511/250/150/230/160/660/79
Most frequent other events
Most frequent other events
EventGroup 1 (Infant Series)Group 2 (Infant Series)Group 3 (Infant Series)Group 1 (Toddler Dose)Group 2 (Toddler Dose)Group 3 (Toddler Dose)Group 4 (2 Catch-Up Doses)Group 5 (1 Catch-Up Dose)
PyrexiaGeneral disorders9/1514/511/250/150/230/160/660/79
Rash maculo-papularSkin and subcutaneous tissue disorders0/1510/510/250/150/230/161/660/79
Injection site erythemaGeneral disorders1/1510/510/250/150/230/160/660/79
Injection site swellingGeneral disorders1/1510/510/250/150/230/160/660/79
ConvulsionNervous system disorders1/1510/510/250/150/230/160/660/79
CryingNervous system disorders1/1510/510/250/150/230/160/660/79

Baseline characteristics

Age, Customized
Age, Customized(Months)13vPnC Group 1 (3 Doses Infant Series and 1 Toddler Dose)13vPnC Group 2 (2 Doses Infant Series and 1 Toddler Dose)13vPnC Group 3 (1 Dose Infant Series and 1 Toddler Dose)13vPnC Group 4 (2 Catch-Up Doses)13vPnC Group 5 (1 Catch-Up Dose)Total
Mean1.4 ± 0.64.4 ± 0.87.1 ± 1.615.2 ± 3.440.1 ± 11.112.9 ± 15.9
Sex: Female, Male
Sex: Female, Male(Participants)13vPnC Group 1 (3 Doses Infant Series and 1 Toddler Dose)13vPnC Group 2 (2 Doses Infant Series and 1 Toddler Dose)13vPnC Group 3 (1 Dose Infant Series and 1 Toddler Dose)13vPnC Group 4 (2 Catch-Up Doses)13vPnC Group 5 (1 Catch-Up Dose)Total
Female7323113647190
Male7828143132183
08

Study locations

21 sites
  • Pfizer Investigational Site
    Akiak, Alaska 99552, United States
  • Pfizer Investigational Site
    Bethel, Alaska 99559, United States
  • Pfizer Investigational Site
    Chefornak, Alaska 99561, United States
  • Pfizer Investigational Site
    Chevak, Alaska 99563, United States
  • Pfizer Investigational Site
    Eek, Alaska 99578, United States
  • Pfizer Investigational Site
    Emmonak, Alaska 99581, United States
  • Pfizer Investigational Site
    Hooper Bay, Alaska 99604, United States
  • Pfizer Investigational Site
    Kasigluk, Alaska 99609, United States
  • Pfizer Investigational Site
    Kongiganak, Alaska 99545, United States
  • Pfizer Investigational Site
    Kotlik, Alaska 99620, United States
  • Pfizer Investigational Site
    Kwethluk, Alaska 99621, United States
  • Pfizer Investigational Site
    Kwigillingok, Alaska 99622, United States
  • Pfizer Investigational Site
    Mtn. Village, Alaska 99632, United States
  • Pfizer Investigational Site
    Napaskiak, Alaska 99559, United States
  • Pfizer Investigational Site
    Newtok, Alaska 99559, United States
  • Pfizer Investigational Site
    Nunapitchuk, Alaska 99641, United States
  • Pfizer Investigational Site
    Russian Mission, Alaska 99657, United States
  • Pfizer Investigational Site
    Scammon Bay, Alaska 99662, United States
  • Pfizer Investigational Site
    Toksook Bay, Alaska 99637, United States
  • Pfizer Investigational Site
    Tuluksak, Alaska 99679, United States
  • Pfizer Investigational Site
    Upper Kalskag, Alaska 99607, United States
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2009, a primary completion of Sep 2010 and a completion of Sep 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2012, 1 year 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 27, 2008
First posted
Aug 29, 2008
Start
Jan 2009
Primary completionActual
Sep 2010
CompletionActual
Sep 2010
Results first posted
Feb 10, 2012
Last update
Mar 15, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 15, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00743652
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Aug 29, 2008
Start date
Jan 2009
Primary completion
Sep 2010
Completion
Sep 2010
Results posted
Feb 10, 2012
Last update
Mar 15, 2012

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: 13-valent pneumococcal vaccine

Start the discussion